24×7 Emergency Care

1-8-31/1, Minister Road, Secunderabad, Telangana 500003

Conditions

AUTONOMIC NERVOUS SYSTEM DISORDERS

Multiple System Atrophy with Autonomic Features — Specialist Diagnosis and Care in Hyderabad at KIMS

Multiple System Atrophy (MSA) is a progressive, fatal neurodegenerative disorder characterised by a combination of autonomic failure, parkinsonism, and/or cerebellar ataxia, in varying combinations. It is caused by the accumulation of misfolded alpha-synuclein protein as glial cytoplasmic inclusions (GCIs) in oligodendrocytes — the insulating cells of white matter axons — throughout the brainstem, cerebellum, basal ganglia, and spinal cord autonomic centres. Unlike Parkinson's disease (where Lewy bodies accumulate in neurons), MSA deposits are in glial cells and produce a much more aggressive and widespread neurodegeneration.

View Our Specialists

MSA is a progressive fatal neurodegenerative disorder caused by the accumulation of misfolded alpha-synuclein protein as glial cytoplasmic inclusions (GCIs) in oligodendrocytes (the white matter-insulating cells) — unlike Parkinson's disease where alpha-synuclein accumulates as Lewy bodies in neurons. GCIs in oligodendrocytes produce multi-system degeneration of the striatum, substantia nigra, pontine nuclei, inferior olives, Purkinje cells, and IML (spinal cord autonomic centre). Prevalence: 3–5 per 100,000; onset 6th decade; median survival 9–10 years. Two motor subtypes: MSA-P (parkinsonism predominant, most common in India) and MSA-C (cerebellar ataxia predominant). Both share severe autonomic failure: orthostatic hypotension, urinary dysfunction, erectile dysfunction (earliest symptom in males), constipation, reduced sweating. The levodopa response test is the clinical watershed: PD = dramatic, sustained (≥30–70% improvement); MSA = modest (<30%), short-lived, often worsened by levodopa-induced hypotension. Stridor (30–40% of MSA): vocal cord paralysis from nucleus ambiguus degeneration; major cause of sudden death during sleep; managed with nocturnal CPAP. MRI: hot cross bun sign (cruciform T2 hyperintensity in pons) + putaminal hypointensity + putaminal rim sign (SWI).

Alpha-synuclein in oligodendrocytes — not neurons: PD: alpha-synuclein accumulates as LEWY BODIES in NEURONS (particularly dopaminergic neurons in the substantia nigra). MSA: alpha-synuclein accumulates as GLIAL CYTOPLASMIC INCLUSIONS (GCIs) in OLIGODENDROCYTES (the myelin-producing support cells of white matter). This cellular difference explains why MSA is more aggressive and more widespread: oligodendrocyte dysfunction disrupts myelin throughout the brainstem, cerebellum, and spinal cord autonomic centres.
Levodopa response test — the clinical watershed: PD: dramatic, sustained improvement with levodopa (≥30–70% motor improvement, persisting for years). MSA-P: modest improvement at best (<30%), short-lived (months, not years), often complicated by worsening orthostatic hypotension. A robust, sustained levodopa response argues strongly FOR PD. A poor response — or a response limited by orthostatic hypotension — argues FOR MSA. This trial response is the most important clinical decision point in differentiating MSA-P from PD.
Stridor — the dangerous respiratory complication: Stridor (30–40% of MSA patients): a harsh, high-pitched inspiratory noise from laryngeal abductor muscle paralysis (degeneration of the nucleus ambiguus). Initially nocturnal, can progress to daytime stridor and acute respiratory obstruction. Stridor during sleep is a MAJOR cause of sudden death in MSA. Every MSA patient with snoring, witnessed apnoeas, or unexplained nocturnal awakenings requires urgent polysomnography. Management: nocturnal CPAP (4–12 cmH₂O); tracheostomy for CPAP failure or severe daytime stridor.
Hot cross bun sign — MSA MRI signature: On axial T2-weighted MRI through the pons: a cruciform (cross-shaped) area of T2 hyperintensity produced by degeneration of the pontocerebellar fibres while the corticospinal tracts are relatively spared. This resembles the cross on a hot cross bun and is highly characteristic of MSA, most often seen in MSA-C (cerebellar subtype) and also in MSA-P. It is strongly supportive of the diagnosis but not pathognomonic — MRI findings in MSA must always be interpreted in the context of the clinical picture and exclusion of mimics. MSA remains a clinical diagnosis. In MSA-P: putaminal hypointensity on T2 and putaminal rim sign on SWI (a hypointense rim around the posterior putamen). Neither finding is seen in Parkinson's disease.
Erectile dysfunction — the earliest MSA symptom in males: In males with MSA, erectile dysfunction is frequently the EARLIEST symptom of the disease, preceding parkinsonism or cerebellar signs by months to years. It results from degeneration of the sacral autonomic centre controlling penile vascular reflex. Asking about erectile function in male patients presenting with early parkinsonism is an important part of the MSA workup. Its early onset in MSA (compared to its late or absent occurrence in PD without autonomic failure) is a key differentiating historical feature.
Dual BP management — daytime OH + nocturnal supine hypertension: MSA autonomic failure impairs BP regulation in BOTH directions: inadequate vasoconstriction on standing (causing OH) AND inadequate vasodilation when supine (causing nocturnal supine hypertension). Managing both: daytime OH (midodrine not after 6pm; fludrocortisone; compression; fluids) + nocturnal hypertension (HOB elevation 30° — most important single intervention; glyceryl trinitrate patch at bedtime; short-acting antihypertensive at night if BP >160 mmHg supine). 24-hour ambulatory BP monitoring at KIMS guides treatment.
REM sleep behaviour disorder — the prodrome of MSA: REM sleep behaviour disorder (RBD) — acting out dreams during REM sleep, often with punching, kicking, shouting — is present in >85% of MSA patients and frequently PRECEDES the motor diagnosis by years. RBD is detected on polysomnography. In a patient with early parkinsonism, a history of RBD strongly supports MSA (or DLB or PD with Lewy body pathology) over essential tremor or drug-induced parkinsonism. RBD treatment: melatonin 2–6 mg at bedtime; clonazepam 0.5–1 mg at bedtime.

Fact	Details
Pathology	Alpha-synuclein GCIs in oligodendrocytes (vs PD: Lewy bodies in neurons) · Multi-system degeneration: striatum + SN + pontine nuclei + IML + Purkinje cells · More aggressive than PD
Levodopa response	MSA: modest <30%, short-lived, worsened by levodopa-induced OH · PD: dramatic ≥30–70%, sustained for years · Key clinical differentiator
Autonomic failure	Severe within 2 years (vs PD: mild, late) · OH + urinary dysfunction + constipation · Erectile dysfunction EARLIEST symptom in males
Stridor	30–40% of MSA · Vocal cord paralysis (nucleus ambiguus degeneration) · Major cause of sudden death during sleep · Polysomnography + CPAP titration
MRI signature	Hot cross bun sign: cruciform T2 in pons (MSA-C) · Putaminal hypointensity + putaminal rim sign SWI (MSA-P) · Middle cerebellar peduncle T2 hyperintensity
Dual BP management	Daytime OH: midodrine (not after 6pm) + fludrocortisone · Nocturnal supine HT: HOB elevation 30° + short-acting antihypertensive at bedtime · 24h ABPM guides treatment
Prognosis	Median survival 9–10 years · No disease-modifying treatment · Autonomic management + stridor treatment = most impactful interventions · Advance care planning important

About This Condition

Multiple System Atrophy at a Glance

Prevalence

3–5 per 100,000 · Onset typically in 6th decade · Median survival 9–10 years from diagnosis.

Pathology

Alpha-synuclein GCIs in oligodendrocytes · Multi-system degeneration: striatum · substantia nigra · pontine nuclei · inferior olives · Purkinje cells · IML (intermediolateral column) of spinal cord (autonomic centre).

Two motor subtypes

MSA-P: predominant parkinsonism (akinesia, rigidity, postural instability) · MSA-C: predominant cerebellar ataxia (limb and gait ataxia, dysarthria, nystagmus).

Autonomic features

Orthostatic hypotension (≥20/10 mmHg fall on standing) · Urinary dysfunction (urgency, incontinence, incomplete emptying) · Erectile dysfunction (often the earliest feature in males) · Constipation · Reduced sweating.

Red flag features distinguishing MSA from PD

Severe orthostatic hypotension early in the disease · Stridor (harsh inspiratory noise from vocal cord paralysis — rare in PD) · Poor or no response to levodopa · Rapid progression · Absence of significant rest tremor · Early falls (within 3 years) · Cerebellar signs.

MRI signature

Hot cross bun sign: cruciform T2 hyperintensity in the pons (from pontine fibre degeneration) · Putaminal hypointensity + putaminal rim sign (SWI) · Cerebellar and middle cerebellar peduncle atrophy.

Stridor

Vocal cord paralysis / Laryngeal abductor weakness · Stridor during sleep · Can progress to respiratory obstruction · CPAP or tracheostomy.

Treatment

No disease-modifying treatment · Midodrine + fludrocortisone for OH · Oxybutynin / mirabegron for OAB · Sildenafil for ED · CPAP for stridor · Levodopa trial (benefit limited and temporary in most MSA-P) · Botulinum toxin for dystonia.

India note

Underdiagnosed (misdiagnosed as PD) · Levodopa non-response is the key differentiating clue · MSA-P most common in India · Autonomic testing at KIMS for suspected MSA.

About This Condition

Multiple System Atrophy — Alpha-Synuclein Oligodendroglial Disease with Autonomic Predominance

MSA affects approximately 3–5 per 100,000 people and has a median age of onset in the sixth decade. Median survival from diagnosis is 9–10 years — significantly shorter than Parkinson's disease. MSA is classified into two motor subtypes: MSA-P (parkinsonian variant, with predominant parkinsonism — most common) and MSA-C (cerebellar variant, with predominant ataxia). Both subtypes share the defining feature of significant autonomic failure, which is often the most disabling aspect of the condition and frequently precedes the motor features by months to years. In India, MSA is significantly underdiagnosed — most patients are initially diagnosed as Parkinson's disease and only correctly identified as MSA when they fail to respond to levodopa or develop the characteristic autonomic and motor features that do not fit PD.

Specialist Consultation

Speak directly with the KIMS movement disorders and autonomic neurology team — coordinated for the MSA assessment including autonomic function testing, MRI for the hot cross bun and putaminal signs, polysomnography for stridor, and multidisciplinary management.

040-44885000Movement disorders and autonomic neurology line

The Levodopa-Response and Autonomic-Failure Differentiators

Distinguishing MSA from Parkinson's Disease

The levodopa response test — the clinical watershed

Parkinson's disease typically produces a dramatic, sustained response to levodopa: most PD patients achieve 30–70% improvement in motor function with levodopa, which persists for years. MSA-P produces a much more limited levodopa response: approximately 30–40% of MSA-P patients show some initial benefit, but the response is typically modest (less than 30% motor improvement), short-lived (lasting months, not years), and often complicated by levodopa-induced hypotension (which is already present from autonomic failure). A robust, sustained levodopa response argues strongly for PD; a poor response — or a response limited by orthostatic hypotension — argues for MSA. This trial response is a major decision point in the diagnostic workup at KIMS.

Autonomic failure — the hallmark and most disabling feature

In Parkinson's disease, autonomic dysfunction is mild to moderate and typically develops late in the disease course (years after the motor onset). In MSA, severe autonomic failure often develops within the first 2 years of the motor symptoms and is disproportionately severe relative to the degree of motor impairment. The specific pattern: orthostatic hypotension (often severe — BP falls of 50+ mmHg on standing, causing recurrent syncope) · Urinary dysfunction (urgency + frequency early, progressing to urinary retention requiring catheterisation) · Erectile dysfunction (often the earliest symptom of MSA in male patients, presenting before any motor symptoms) · Constipation (severe, intractable). The severity and early onset of autonomic failure in MSA has major management implications: midodrine and fludrocortisone for OH, urological management for bladder dysfunction.

Stridor — the dangerous respiratory emergency of MSA

Stridor — a harsh, high-pitched inspiratory noise from the larynx — occurs in 30–40% of MSA patients and results from laryngeal abductor muscle paralysis (the muscles that hold the vocal cords open during inspiration are weakened by MSA degeneration of the nucleus ambiguus). It is usually nocturnal initially (during sleep) and can progress to daytime stridor and acute respiratory obstruction during intercurrent illness. Nocturnal stridor in MSA is a major cause of sudden death (upper airway obstruction during sleep). Management: (1) Continuous positive airway pressure (CPAP) during sleep keeps the vocal cords separated · (2) Tracheostomy in severe or refractory stridor. Any MSA patient with a history of snoring, witnessed apnoeas, or unexplained nocturnal awakenings should have an urgent sleep study (polysomnography with laryngeal EMG).

MRI brain — the imaging signature of MSA

The MRI brain findings in MSA are among the most distinctive in neurodegenerative disease. Hot cross bun sign: on axial T2 MRI through the pons, a cruciform (cross-shaped) area of T2 hyperintensity within the pons, produced by selective degeneration of the pontocerebellar fibres (which run in a cross pattern through the pons) while the corticospinal tracts (which are more lateral and posterior) are relatively spared. This sign resembles the cross on a hot cross bun and is a highly characteristic imaging feature of MSA, most commonly seen in MSA-C (cerebellar subtype) and also in MSA-P. It is not pathognomonic — similar pontine changes can occur in other conditions including some spinocerebellar ataxias. MSA is a clinical diagnosis; MRI findings are supportive and must be interpreted alongside the clinical phenotype and exclusion of mimics. Putaminal changes: in MSA-P, the putamen shows T2 hypointensity (from iron deposition) and, on susceptibility-weighted imaging (SWI), a putaminal rim sign (a hypointense rim around the posterior putamen) — not seen in Parkinson's disease. Middle cerebellar peduncle T2 hyperintensity: reflects pontocerebellar fibre degeneration. Important note on MRI interpretation: MSA is a clinical diagnosis per the MDS 2022 consensus criteria. MRI findings — including the hot cross bun sign and putaminal changes — are supportive imaging features that increase diagnostic confidence, but they do not independently confirm MSA.

Diagnosis at KIMS

MSA is diagnosed at KIMS through a structured four-stage workflow that applies the MDS 2022 consensus criteria (probable and possible MSA), runs the full autonomic function battery (tilt table, 24-hour ABPM, QSART, urodynamics), uses DaT-SPECT and FDG-PET as adjunctive imaging (putaminal, brainstem, and cerebellar hypometabolism support MSA), and adds polysomnography with laryngeal EMG to detect REM sleep behaviour disorder and the stridor mechanism that requires CPAP titration :

Diagnostic criteria — MDS consensus criteria 2022

Definite MSA: requires post-mortem pathological confirmation. Probable MSA: autonomic dysfunction (OH ≥20/10 mmHg or urinary dysfunction) + either parkinsonism with poor levodopa response OR cerebellar syndrome · Onset before age 75 · No alternative explanation. Possible MSA: one motor syndrome (parkinsonism or cerebellar) + one autonomic or other MSA feature + possible MSA imaging or biomarker.

Autonomic function testing

Tilt table test: BP and HR on standing · 24-hour ambulatory BP monitoring: nocturnal hypertension + daytime OH · QSART: severely reduced or absent sweat output in MSA (IML degeneration) · Urodynamics: neurogenic bladder pattern · Cardiovascular autonomic battery: Valsalva manoeuvre, HRV.

DaT-SPECT and FDG-PET

DaT-SPECT (dopamine transporter imaging): abnormal in both MSA-P and PD (does not distinguish). FDG-PET: hypometabolism in the putamen, brainstem, and cerebellum in MSA · Posterior cortical-parietal hypometabolism in DLB · Striatal FDG-PET is an important adjunct to distinguish MSA from PD and DLB.

Polysomnography — for REM sleep behaviour disorder and stridor

REM sleep behaviour disorder (RBD): acting out dreams during REM sleep · Present in >85% of MSA · Often predates the motor diagnosis by years · Laryngeal EMG during polysomnography: detects paradoxical vocal cord adduction during inspiration (stridor mechanism) · Guides CPAP pressure titration.

Treatment

Management at KIMS

Autonomic, Motor, and Multidisciplinary Care

Autonomic Failure — Orthostatic Hypotension:

Supine hypertension management: The same patients with daytime OH often develop dangerous nocturnal hypertension (BP >150 supine during sleep) · Glyceryl trinitrate patch at bedtime · Short-acting antihypertensive at night · HOB elevation (reduces supine venous return).

Urinary dysfunction: Urgency/OAB: oxybutynin 2.5–5 mg TDS or mirabegron 25–50 mg daily · Incomplete emptying: clean intermittent self-catheterisation (CISC) or suprapubic catheter for severe retention.

Constipation: Macrogol (polyethylene glycol) · Docusate · Rectal interventions if severe.

Erectile dysfunction: Sildenafil 25–50 mg (caution with OH) · Check BP before and after.

Motor Management:

Levodopa trial: Levodopa/carbidopa up to 1 g/day · Continue if ≥30% motor benefit · Stop if worsening OH without motor benefit.

Botulinum toxin: For focal dystonia (laryngeal injection for stridor — use with extreme caution) · Limb dystonia.

CPAP for stridor: Nocturnal CPAP 4–12 cmH₂O titrated during polysomnography · Tracheostomy for CPAP failure or severe daytime stridor.

Multidisciplinary Rehabilitation: Physiotherapy: postural management, gait aids, fall prevention · Speech therapy: dysarthria, dysphagia, and voice volume (LSVT-LOUD) · OT: ADL adaptation, home modification · Nutritional support: gastrostomy when dysphagia is severe · Psychological support: MSA diagnosis is devastating and requires ongoing psychological support for the patient and family.

Related Conditions

Multiple system atrophy belongs to the family of autonomic nervous system disorders evaluated and managed at KIMS Neuroscience. Explore related conditions or return to the hub.

Dysautonomia Familial Dysautonomia

FAQs

Frequently Asked Questions

The features you describe are exactly the red flags that distinguish Multiple System Atrophy from Parkinson's disease: (1) Poor or absent levodopa response: PD typically produces dramatic motor improvement with levodopa; MSA-P produces minimal or no lasting benefit. (2) Severe early orthostatic hypotension: in PD, significant OH typically develops late in the disease; in MSA, it often develops within the first 2 years and can be severe. (3) Early urinary dysfunction: urgency, incontinence, or retention appearing early in the disease is far more characteristic of MSA than PD. The combination of all three — levodopa non-response, early severe OH, and early bladder dysfunction — in a parkinsonian patient is highly specific for MSA-P. MRI at KIMS will be examined for the putaminal hypointensity and rim sign that support MSA. The management implications: midodrine and fludrocortisone for the OH are now the priority · Levodopa may be continued at the current dose but dose escalation is unlikely to help · Bladder management (oxybutynin and/or CISC) is initiated. Call 040-44885000.

Yes — this is a significant concern in MSA. Stridor (from vocal cord paralysis in MSA) and sleep-disordered breathing are major causes of sudden death in MSA patients during sleep. The loud snoring and breathing pauses you describe warrant an urgent sleep study (polysomnography) at KIMS to characterise the breathing pattern and determine whether nocturnal CPAP is needed. Nocturnal CPAP — at a pressure sufficient to keep the upper airway open throughout the night — is the standard management and significantly reduces the risk of nocturnal respiratory obstruction. Additionally: your mother should sleep in a lateral position rather than on her back (back-sleeping worsens upper airway obstruction) · Any respiratory infection should be treated promptly as respiratory reserve is reduced in MSA. Call 040-44885000 for an urgent sleep study referral.

Yes — the pattern of daytime orthostatic hypotension combined with nocturnal supine hypertension is a characteristic and challenging feature of MSA autonomic failure, and it directly reflects the loss of autonomic blood pressure regulation in both directions. The autonomic failure prevents appropriate constriction when standing (causing OH) and also prevents appropriate vasodilation when supine (causing nocturnal hypertension). Management: (1) Midodrine should not be taken after 6 pm or within 4 hours of bedtime · (2) Head-of-bed elevation to 30° (semi-recumbent sleeping): the partial upright position reduces venous return and lowers supine BP · (3) Short-acting antihypertensive at bedtime if supine BP is consistently above 160 mmHg (glyceryl trinitrate patch, nifedipine, or hydralazine) · (4) Evening fluid restriction (reduces nocturnal BP without daytime dehydration). This management requires careful 24-hour BP monitoring at KIMS to optimise treatment without worsening daytime OH. Call 040-44885000.

MSA is a serious condition and you deserve a direct, honest answer alongside realistic hope. The median survival after MSA diagnosis is 9–10 years, though individual variation is significant. The disease progresses, but the rate of progression varies. What we can meaningfully achieve with specialist management: (1) Significantly reduce the burden of orthostatic hypotension with midodrine + fludrocortisone — this alone markedly improves daily function and reduces falls. (2) Manage the bladder dysfunction to maintain continence and prevent recurrent UTIs. (3) Manage stridor to reduce the risk of sudden nocturnal death — this is potentially life-extending. (4) Physiotherapy and speech therapy to maintain function and communication for longer. (5) Advance care planning: MSA is one of the conditions where having clear conversations about goals of care, resuscitation preferences, and what the patient wants as the disease progresses is genuinely important and beneficial. This is not giving up — it is planning to live as well as possible for as long as possible. At KIMS, the MSA multidisciplinary team provides this planning alongside the clinical management. Call 040-44885000.

Parkinson's medications that are not working. A blood pressure that collapses every morning. Snoring that has become dangerous. A diagnosis that took years to get right. Multiple System Atrophy is not Parkinson's disease — and managing it correctly makes a significant difference to daily life and survival.

At KIMS Hyderabad, the movement disorders and autonomic neurology team provides the full MSA assessment and multidisciplinary care programme. Call 040-44885000.

040-44885000

International enquiries: info@kimsneurosciences.com